The three-dimensional dose (3D) distribution of intensity-modulated radiation therapy (IMRT) was verified based on electronic portal imaging devices (EPIDs), and the results were analyzed. Thirty IMRT plans of different lesions were selected for 3D EPID-based dose verification. The gamma passing rates of the 3D dose verification-based EPID system (Edose, Version 3.01, Raydose, Guangdong, China) and Delta4 measurements were then compared with treatment planning system (TPS) calculations using global gamma criteria of 5%/3 mm, 3%/ 3 mm, and 2%/2 mm. Furthermore, the dose-volume histograms (DVHs) for planning target volumes (PTVs) as well as organs at risk (OARs) were analyzed using Edose. For dose verification of the 30 treatment plans, the average gamma passing rates of Edose reconstructions under the gamma criteria of 5%/3 mm, 3%/3 mm, and 2%/2 mm were (98.58 AE 0.93)%, (95.67 AE 1.97)%, and (83.13 AE 4.53)%, respectively, whereas the Delta4 measurement results were (99.14% AE 1.16)%, (95.81% AE 2.88)%, and (84.74% AE 7.00)%, respectively. The dose differences between Edose reconstructions and TPS calculations were within 3% for D 95% , D 98% , and D mean in each PTV, with the exception that the D 98% of the PTV-clinical target volume (CTV) in esophageal carcinoma cases was (3.21 AE 2.33)%. However, the larger dose deviations in OARs (such as lens, parotid gland, optic nerve, and spinal cord) can be determined based on DVHs. The difference was particularly obvious for OARs with small volumes; for example, the maximum dose deviation for the lens reached (À6.12 AE 5.28)%. A comparison of the results obtained with Edose and Delta4 indicated that the Edose system could be applied for 3D pretreatment dose verification of IMRT. This system could also be utilized to evaluate the gamma passing rate of each treatment plan. Furthermore, the detailed dose distributions of PTVs and OARs could be indicated based on DVHs, providing additional reliable data for quality assurance in a clinic setting.
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Because the Edose system constitutes a novel device using new technology for IMRT pretreatment dose verification, it was necessary to ensure its accuracy in clinical application. This study therefore aimed to evaluate the accuracy of the Edose system by comparing its reconstructed results with those measured using more established methods, namely the Delta4 device. [16] [17] [18] A total of 30 IMRT treatment plans are evaluated in the clinical application study.
| METHODS AND MATERIALS

2.A | Measurement devices
The measurements were performed using the Varian Trilogy ( 
2.B | The theory of 3D dose reconstruction in the Edose system
The Edose system is a QA tool based on the patients' anatomy. This system uses the pixel values of images captured by EPID from treatment fields in air without a phantom/patient as input parameters.
The images are then reconstructed into a fluence map of the actually delivered beam through deconvolution and convolution. The CCCS algorithm was used for the 3D dose calculations and the 3D gamma evaluations. The theoretical formulas 19, 20 of the fluence maps were reconstructed from the EPID image in the Edose system as follows:
where
where "a", which is proportional to monitor units (MU), is a coefficient denoting the EPID pixel values, "P ij " denotes the EPID image pixel values, and "K 1 (d ij )" is the EPID's scattering kernel and represents the energy scattering distribution after the interaction of the incident photon with EPID. In addition, l 1 and l 2 are the attenuation coefficients, which depend on the energy and the materials, c is the ratio constant, "K 2 (d ij )" is the fuzzy convolution kernel, which is the boundary factor for depicting the penumbra, l 3 affects the gradient of the penumbra, "ƒ(r ij )" is the Gaussian distribution function, which is introduced for shape correction, and e, r, and C r are obtained by comparing the profile after the reconstruction, mainly aimed at the large field to execute the adjustment. Furthermore, these three parameters reflect the upward curve of the saddle-shaped part of the profile. The variables "K 2 (d ij )" and "ƒ(r ij )" can correct the profile shape at various depths. c, l 1 , l 2 , l 3 , C r , e, and r are parameters for the detector kernel and were determined using the central point doses, which were measured in air for fields of 3 cm 9 3 cm to 25 cm 9 25 cm using an ionization chamber.
The parameters were constants once the fit procedure was completed as a result of the invariant structure of EPID. The EPID-based fluence maps for fields of 3 cm 9 3 cm to 25 cm 9 25 cm were compared with the ionization chamber results. The total scatter factor (S c,p ) and the dose profiles were measured using an ionization chamber with a buildup cap in air by scanning an empty 3D water tank (MP3, PTW, Germany) at an SAD of 100 cm. The values of the parameters were determined when the deviation between the ion chamber measurements and the EPID-based fluence maps was less than 2%. The values of the parameters applied in this study were c = 0.00013, l 1 = 11.3000, l 3 = 15.000, C r = 0.028, e = 6.000, and r = 5.000.
2.C | Clinical applications and evaluation of Edose
Prior to evaluation, comprehensive tests and evaluations to the Edose system were performed using the film and ionization chamber (IC) with uniform and human phantoms. The ionization chamber and radiochromic film were selected for measuring the point and planar doses for the single square and its combined fields and IMRT plans, and the corresponding results were compared to those reconstructed using Edose. The results showed that the point dose measured by the Edose agreed within 0.5% with the ionization chamber measurement in a uniform phantom. A minimum gamma pass rate of 95% was achieved for the comparison between Edose reconstructed dose maps and the planned dose maps when using the dose difference criterion of 5% of the maximum dose and a distance-to-agreement criterion of 3 mm (henceforth referred to as 5%/3 mm) and 3%/3 mm gamma criteria. The details are provided in our previously published manuscript. 21 In the present study, 3D dose reconstruction results obtained using the Edose system and measured with Delta4
were compared with those calculated by TPS to verify the feasibility of the Edose system. Thirty IMRT patient plans, including 10 nasopharyngeal carcinoma (NPC) plans, 10 esophageal carcinoma (EPC) plans, and 10 rectal cancer (REC) plans, were selected randomly for the 3D dose verification of Edose.
2.C.1 | Treatment plan
Thirty IMRT patient plans were optimized and calculated using an The treatment plans were recalculated with Delta4 without changing the monitor units and were then delivered to the Delta4 phantom.
2.C.2 | Methods of measurements
The panel of EPID detectors was positioned at the isocenter with a source-to-detector distance (SDD) of 100 cm without any attenuat- 
2.C.3 | Evaluation methods
An analytical method for 3D gamma evaluations 22 was applied to compare the 3D dose distributions that were reconstructed using HUANG ET AL.
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Edose and measured using Delta4 with those obtained with the TPS.
A dose difference criterion of 5% of the maximum dose and a distance-to-agreement criterion of 3 mm were selected. A 3%/3 mm criterion and a more rigid 2%/2 mm criterion were also evaluated.
The gamma evaluation was global for both devices, and the threshold used for the dose analysis was more than 10% of the prescribed dose. The same areas that were used for the dose comparisons were defined as regions of interest (ROIs). A graphics processing unit (GPU) operation was employed in the system to improve the efficiency of the 3D gamma calculation. 23, 24 Dose-volume histograms (DVHs) for both target areas and OARs were also compared between the TPS and the Edose system. The target areas were set as the PTVs, which were created by a 5 mm 
| RESULTS
3.A | Gamma passing rate
The gamma passing rates obtained through the Edose reconstructions and Delta4 measurements were compared with the TPS calculations. Figure 1 shows the range of the gamma passing rates of 30 selected cases at the gamma criteria of 5%/3 mm, 3%/3 mm and 2%/2 mm. The narrow range showed the good reproducibility and stability of the response obtained using the Edose system. Overall, the range of the gamma passing rate detected with Delta4 was greater than that detected with Edose. Figure 2 illustrates the gamma passing rates for the REC, EPC, and NPC plans as well as all 30 plans under the three above-mentioned gamma criteria. The comparison results are expressed as the means AE SD in Fig. 2 and Table 1 . As illustrated in Fig. 2 , a similar gamma passing rate for NPC and EPC was obtained under the 5%/ 3 mm criterion. In contrast, under the severe criteria of 3%/3 mm and 2%/2 mm, the gamma passing rate obtained for esophageal cases was higher than that found for NPC cases. Under all three criteria, the best passing rate was found for REC. Furthermore, the small SD shown in Fig. 2 
3.B | DVH comparison between Edose and TPS
In comparison to the TPS calculations, the ΔD 95 , ΔD mean , and ΔD 98 of the PTVs obtained using Edose showed that the deviations were less than 3%, with the exception of the ΔD 98 found for the PTV-CTV in esophageal carcinoma patients, which was (3.21 AE 2.33)%, as shown in In other words, the values found for the deviation of these OARs were greater than AE 3%.
Using the NPC plan as an example, Fig. 3 shows the 3D dose distributions in three axial slices, and gamma analysis revealed that passing rate with the 3%/3 mm criterion was 96.8%. Overall, for all plans in this paper, the dose distributions had an excellent agreement between the TPS original plans and the reconstructed by Edose. The slice-by-slice comparisons revealed no significant dose differences.
| DISCUSSION
Previous studies [16] [17] [18] have indicated that Delta4 is superior in IMRT and VMAT patient pretreatment quality assurance. Therefore, Delta4
was selected in this study to compare the gamma analysis for the clinical cases with that reconstructed using Edose. The comparisons performed in this study showed that the Edose system could be suitably applied for clinical dose verification. The results showed that 3D dose verification (Edose) can provide not only the gamma passing rate but also the dose-volume relationship for the PTVs and OARs.
In addition, the results show that Edose provides more detailed information and more accurate data for QA (such as the DVH of PTVs and OARs) in clinical radiotherapy. As a result, this system could further improve the QA of IMRT plans. In this study, the gamma analysis included comparisons only with Delta4 but did not
Comparison of the average gamma passing rates for the 30 IMRT cases obtained from Edose and Delta4 measurements. The red circle and the black box represent the mean values of the gamma passing rates obtained using Edose and Delta4, respectively, and the error bars represent the SDs of the corresponding gamma passing rates.
T A B L E 1 Comparison of average gamma passing rates obtained using Edose and TPS for 30 IMRT cases.
Gamma criterion
Gamma passing rate (mean AE SD) % The gamma passing rate reached 92% under the criteria of 5%/ 3 mm and 3%/3 mm. Currently, a gamma passing rate of at least 88% under 3%/3 mm is widely used to indicate the feasibility of IMRT plans, 25 and many radiotherapy central believe that the gamma evaluation method is reliable and effective for IMRT treatment verification. The results reflect in Fig. 2 show that Edose is more suitable for QA of IMRT due to its small deviation and high stability. 
Evaluated Organs
Edose vs. TPS The analysis of DVHs (as shown in Table 2 ) indicated that the differences in target areas were small, and larger dose deviations were found in small-volume OARs. For example, the dose deviations obtained for the lens, parotid gland, optic nerve, and lungs in EPC and for the spinal cord exceeded 3% and even reached 6%. Furthermore, the larger SD of the OARs indicated that OARs are more sensitive than PTVs to changes in dosage. This pattern, which is illustrated in Fig. 4 , was obtained because these OARs have a smaller volume; smaller dose differences would lead to a larger dose deviation in these OARs. 28 The same results were obtained in a previous study conducted by Chen. 29 The gamma passing rate is not sufficient for evaluating the feasibility of an IMRT plan, because it
Comparison of dose distributions in axial, coronal and sagittal views obtained using Edose (dotted lines) and calculated using the TPS (solid lines) for one of the NPC patients. The gamma passing rate using the 3%/3 mm global criterion was 96.8%. The green isodose line represents the 45-Gy distribution, the blue isodose line represents the 54-Gy distribution, the pink isodose line represents the 60-Gy distribution, the red isodose line represents the 66-Gy distribution, and the black isodose line represents the 68-Gy distribution. | 103 cannot accurately reflect the dose differences in the target areas and OARs of the anatomical structures of patients. 30, 31 Thus, the highest safe doses for sensitive and important OARs should be adjusted according to the relationship between dose and anatomical structures.
As shown in Table 2 , the deviation between the Edose reconstruction and the TPS calculation was greater than 5%, and this value was obtained for the clinical target areas located close to the skin surface, such as the PTV-GTV-N-R in NPC. This phenomenon is related that the dose distribution is reconstructed using the fluence maps based on EPID. The dose of the built-up region mainly come from the local dose deposition and relatively small contribution from the distal area, which would lead to an inability of the 3D dose verification system (Edose) to amend the dose to the built-up region. In general, only a slight effect on the dose verification accuracy for the IMRT plan was found because the target areas were not too close to the built-up area. However, a certain effect on in vivo measurements could be obtained, because the EPID as a detector for photon rays in the Edose system showed a low-energy response. 32 Therefore, subsequent versions of Edose should correct the scatter in the built-up area to achieve better dose verification results.
| CONCLUSIONS
This study tested a preliminary clinical application of 30 IMRT plans, and the results showed that the EPID-based 3D dose verification system (Edose) was a simple and convenient QA tool for IMRT pretreatment dose verification. The gamma analysis included comparisons with the Delta4 system to validate the accuracy and reliability of the Edose system. The system could provide more clinical data and information through a single measurement. Furthermore, this system could allow a more intuitive and effective assessment for pretreatment plan dose verification. In future work, we would apply more verification tools to compare and verify the EPID-based system, and proceed more detailed verification and clinical applicability of this system.
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